Kaspofungin Viatris (Caspofungin)

Caspofungin belongs to the echinocandin class and works by inhibiting the enzyme responsible for synthesising β‑(1,3)‑D‑glucan, a key structural component of the fungal cell wall. This inhibition weakens the cell wall, leading to osmotic instability and ultimately causing fungal cell death, while sparing human cells that lack this polymer.

The dose of Kaspofungin Viatris is determined by the prescribing healthcare professional based on the specific infection being treated, the patient’s weight, renal and hepatic function, and any concomitant medications. Only a qualified prescriber should set the dosing regimen; it is not self‑adjusted.

Safety data for caspofungin in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified clinician.

To order Kaspofungin Viatris, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Compared with azoles or polyenes, caspofungin (an echinocandin) offers a distinct mechanism targeting the fungal cell wall rather than membrane sterols. This can result in fewer drug‑drug interactions and a lower risk of nephrotoxicity than amphotericin B, while providing potent activity against Candida and Aspergillus species that may be resistant to azoles.

Kaspofungin Viatris should be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Maintaining the cold‑chain ensures drug stability and efficacy.

Kaspofungin Viatris is administered as an intravenous infusion. The initial dose is typically given over a 60‑minute period, followed by daily maintenance infusions as directed by the prescriber. Administration must be performed by qualified healthcare personnel in a clinical setting.

Serious risks include hypersensitivity reactions such as rash, pruritus, or anaphylaxis; severe hepatic dysfunction manifested by marked elevations in liver enzymes or jaundice; and infusion‑related events like chest pain, dyspnea, or hypotension. Patients should be monitored closely for these signs during therapy.

Kaspofungin Viatris should be avoided in patients with known hypersensitivity to caspofungin or any component of the formulation. Caution is also advised for individuals with severe hepatic impairment, uncontrolled renal failure, or those receiving strong CYP3A4 inducers that could markedly reduce drug exposure.